Yabusaki Norimitsu, Fujii Tsutomu, Yamada Suguru, Murotani Kenta, Sugimoto Hiroyuki, Kanda Mitsuro, Nakayama Goro, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro
Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya Center for Clinical Research, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Medicine (Baltimore). 2016 Jul;95(29):e4282. doi: 10.1097/MD.0000000000004282.
Recently, it has been reported that the relative dose intensity (RDI) of adjuvant chemotherapy (AC) influences survival in various cancers, but there are very few reports about RDI in pancreatic ductal adenocarcinoma (PDAC). The optimal timing for initiation of AC for PDAC also remains unknown. The aim of this study was to identify the significance of RDI and the time interval between surgery and initiation of AC on survival of patients with PDAC. Clinicopathological factors that affect RDI were also investigated.A total of 311 consecutive PDAC patients who underwent curative resection between May 2005 and January 2015 were enrolled. Patients who underwent neoadjuvant chemoradiation, had UICC stage IV disease, or had early recurrences within 6 months were excluded, and the remaining 168 cases were analyzed.Patients with RDIs ≥80% (n = 79) showed significantly better overall survival (OS) compared to patients with RDIs <80% (n = 55) (median survival time (MST): 45.6 months, 26.0 months, P < 0.001). Patients with no AC (n = 34) showed the worst OS (MST: 20.8 months). Whether the AC was initiated earlier or later than 8 weeks after surgery did not influence survival, either in patients with RDIs ≥80% (P = 0.79) or in those with <80% (P = 0.73). Patients in the S-1 monotherapy group (n = 49) showed significantly better OS than patients in the gemcitabine monotherapy group (n = 51) (MST: 95.0 months, 26.0 months, respectively; P = 0.001). Univariate analysis conducted after adjusting for the chemotherapeutic drug used identified several prognostic factors; male gender (P = 0.01), intraoperative blood transfusion (P = 0.005), lymph node metastasis (P = 0.03), and postoperative WBC count (P = 0.03). Multivariate analysis identified intra-plus postoperative blood transfusion (P = 0.002) and high postoperative platelet-to-lymphocyte ratios (PLR) (P = 0.04) as independent predictors of poor RDI.Efforts to maintain RDI had a greater impact on survival than the struggle to start AC early after surgery. Intra-plus postoperative blood transfusion and a high postoperative PLR could be predictive markers of reduced RDI in AC of PDAC patients. Avoidance of perioperative blood transfusions where possible and nutritional support during the perioperative period could maintain adequate RDI and may lead to improved long-term outcome.
最近,有报道称辅助化疗(AC)的相对剂量强度(RDI)会影响多种癌症患者的生存率,但关于胰腺导管腺癌(PDAC)中RDI的报道却很少。PDAC开始AC的最佳时机也尚不清楚。本研究的目的是确定RDI以及手术与开始AC之间的时间间隔对PDAC患者生存的意义。同时还研究了影响RDI的临床病理因素。
纳入了2005年5月至2015年1月期间连续接受根治性切除术的311例PDAC患者。排除接受新辅助放化疗、国际抗癌联盟(UICC)IV期疾病或6个月内早期复发的患者,对其余168例病例进行分析。
RDI≥80%的患者(n = 79)与RDI<80%的患者(n = 55)相比,总生存期(OS)显著更好(中位生存时间(MST):45.6个月,26.0个月,P<0.001)。未接受AC的患者(n = 34)OS最差(MST:20.8个月)。手术8周后早于或晚于开始AC对RDI≥80%的患者(P = 0.79)或<80%的患者(P = 0.73)的生存均无影响。S-1单药治疗组患者(n = 49)的OS显著优于吉西他滨单药治疗组患者(n = 51)(MST:分别为95.0个月和26.0个月;P = 0.001)。在对所用化疗药物进行校正后进行的单因素分析确定了几个预后因素;男性(P = 0.01)、术中输血(P = 0.005)、淋巴结转移(P = 0.03)和术后白细胞计数(P = 0.03)。多因素分析确定术中加术后输血(P = 0.002)和术后高血小板与淋巴细胞比值(PLR)(P = 0.04)是RDI降低的独立预测因素。
努力维持RDI对生存的影响大于术后尽早开始AC的努力。术中加术后输血和术后高PLR可能是PDAC患者AC中RDI降低的预测指标。尽可能避免围手术期输血以及围手术期的营养支持可维持足够的RDI,并可能改善长期预后。